Research programme: immuno-microbials - Evelo Biosciences

Drug Profile

Research programme: immuno-microbials - Evelo Biosciences

Alternative Names: Immuno-microbial therapeutics - Evelo Biosciences; Monoclonal microbial therapeutics - Evelo Biosciences

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Epiva Biosciences
  • Developer Evelo Biosciences
  • Class Anti-inflammatories; Bacteria; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 16 Nov 2017 Evelo Biosciences in-licenses technology and patent estate from Mayo Clinic
  • 16 Nov 2017 Evelo Biosciences has patent protection for monoclonal microbials
  • 11 Jul 2017 Evelo Biosciences plans clinical trials in Autoimmune disorders and Inflammation in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top